Chinook Therapeutics Inc. (NASDAQ: KDNY) is 0.76% higher on its value in year-to-date trading and has touched a low of $10.50 and a high of $21.68 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The KDNY stock was last observed hovering at around $15.37 in the last trading session, with the day’s gains setting it 0.61% off its average median price target of $31.00 for the next 12 months. It is also 60.05% off the consensus price target high of $40.00 offered by 8 analysts, but current levels are 36.08% higher than the price target low of $25.00 for the same period.
Currently trading at $15.98, the stock is 6.73% and -1.71% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.54 million and changing 3.97% at the moment leaves the stock 6.74% off its SMA200. KDNY registered 7.61% gain for a year compared to 6-month gain of 7.25%. The firm has a 50-day simple moving average (SMA 50) of $16.16 and a 200-day simple moving average (SMA200) of $15.59.
The stock witnessed a 2.11% loss in the last 1 month and extending the period to 3 months gives it a 7.75%, and is 7.32% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.13% over the week and 6.78% over the month.
Chinook Therapeutics Inc. (KDNY) has around 105 employees, a market worth around $693.69M and $0.80M in sales. Distance from 52-week low is 52.19% and -26.29% from its 52-week high. The company has generated returns on investments over the last 12 months (-24.50%).
Chinook Therapeutics Inc. (KDNY) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Chinook Therapeutics Inc. (KDNY) is a “Buy”. 8 analysts offering their recommendations for the stock have an average rating of 1.50, where 0 rate it as a Hold and 0 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Chinook Therapeutics Inc. quarterly earnings per share for the current quarter are estimated at -$0.68 with sales reaching $50k over the same period.The EPS is expected to shrink by -20.60% this year, but quarterly earnings will post 72.90% year-over-year. Quarterly sales are estimated to shrink -99.60% in year-over-year returns.
Chinook Therapeutics Inc. (KDNY) Top Institutional Holders
115 institutions hold shares in Chinook Therapeutics Inc. (KDNY), with 4.63M shares held by insiders accounting for 10.93% while institutional investors hold 83.70% of the company’s shares. The shares outstanding are 42.38M, and float is at 18.91M with Short Float at 5.05%. Institutions hold 74.56% of the Float.
The top institutional shareholder in the company is ATP Life Science Ventures, L.P. with over 4.03 million shares valued at $63.9 million. The investor’s holdings represent 9.51% of the KDNY Shares outstanding. As of Dec 30, 2020, the second largest holder is Samsara BioCapital, LLC with 3.17 million shares valued at $50.25 million to account for 7.48% of the shares outstanding. The other top investors are Blackrock Inc. which holds 1.41 million shares representing 3.32% and valued at over $22.34 million, while EcoR1 Capital, LLC holds 2.95% of the shares totaling 1.25 million with a market value of $19.83 million.
Chinook Therapeutics Inc. (KDNY) Insider Activity
The most recent transaction is an insider purchase by DOBMEIER ERIC, the company’s President, CEO. SEC filings show that DOBMEIER ERIC bought 2,000 shares of the company’s common stock on Dec 09 at a price of $13.07 per share for a total of $26150.0. Following the purchase, the insider now owns 56837.0 shares.
Chinook Therapeutics Inc. disclosed in a document filed with the SEC on Dec 08 that DOBMEIER ERIC (President, CEO) bought a total of 2,000 shares of the company’s common stock. The trade occurred on Dec 08 and was made at $13.24 per share for $26483.0. Following the transaction, the insider now directly holds 54837.0 shares of the KDNY stock.
Still, SEC filings show that on Nov 23, DOBMEIER ERIC (President, CEO) acquired 929 shares at an average price of $13.67 for $12699.0. The insider now directly holds 52,837 shares of Chinook Therapeutics Inc. (KDNY).